OUTSOURCED PHARMA CAPACITY UPDATE LARGE MOLECULE VIDEOS
Resilience Capabilities Update May 2026: Large Molecule
An integrated network unites biologics, cell therapy, and drug product with digital systems and teams to speed tech transfer, scale reliably, and ensure delivery from development to commercial.
Rentschler Biopharma Capabilities Update May 2026: Large Molecule
Rentschler Biopharma is a global leading contract development and manufacturing organization (CDMO) focused exclusively on client projects.
Samsung Biologics Capabilities Update May 2026: Large Molecule
Watch this on-demand session to explore the future of global biologics manufacturing, dual-sourcing strategies, and next-generation expansion plans in advanced therapies.
Rezon Bio Capabilities Update May 2026: Large Molecule
Discover how tailored biologics development strategies can improve scalability, reduce tech transfer risk, and create more reliable pathways from early development to commercial supply.
Alcami Capabilities Update May 2026: Large Molecule
Watch this on-demand session to learn risk-based strategies for optimizing biologic drug substance-to-product transitions while minimizing aggregation and process stress.
Cytovance Biologics Capabilities Update March 2026: Large Molecule
How a seasoned development and manufacturing team blends technical depth, reliability, and flexible support to advance large‑molecule programs amid shifting timelines, costs, and regulatory demands.
Fujifilm Biotechnologies Capabilities Update March 2026: Large Molecule
An overview of manufacturing strategies and scaling options shows how aligned systems, smart planning, and flexible models support biologics from early development to commercialization.
ProBio Capabilities Update March 2026: Large Molecule
A new Center of Excellence expands capacity for genetic‑medicine programs with upgraded facilities, streamlined workflows, and early‑stage services that support readiness for PD and IND milestones.
Boehringer Ingelheim Capabilities Update March 2026: Large Molecule
Integrated culture and fermentation systems streamline development, improve scalability, and strengthen continuity throughout the lifecycle of complex biopharmaceutical programs.
OPCU October 2025: Large Molecule
Advance your biotherapeutic with a trusted global CDMO partner offering end-to-end development and manufacturing, supported by state-of-the-art facilities and a commitment to your success.
Nanoform Capacity Update October 2025: Large Molecule
Sergie Letser, Deputy CCO, presents an overview of Nanoform’s novel large molecule nanoforming technology capabilities and current capacity.
Cytovance Biologics Capacity Update October 2025: Large Molecule
Partner with a U.S.-based, trusted CDMO large enough to support every stage of your program, yet agile enough to deliver the dedicated care your project deserves.
From Concept To Market: Mammalian Protein Development And Manufacturing
With proven expertise in process development, optimization, and CGMP manufacturing, Avid offers end-to-end CDMO solutions backed by flexible capacity designed to scale with program needs.
AGC Biologics Capacity Update October 2025: Large Molecule
Michael Brotz provides an in-depth look at our Seattle site and the unique capabilities of the facility, including its single-use and stainless-steel capacity, new manufacturing lines, and more.
Samsung Biologics Capacity Update October 2025: Large Molecule
Accelerate your cancer therapy development with patient-derived organoids — high-fidelity models that enhance translational confidence, streamline discovery, and bring promising treatments to the clinic faster.
Novartis Contract Manufacturing Capacity Update October 2025: Large Molecule
Gain insight into our global manufacturing network, including information about the capabilities of each mammalian and microbial site within the network.
Northway Biotech Capacity Update October 2025: Large Molecule
André Markmann, VP of Business Development, shares insights drawn from over 20 years of experience, more than 185 successful projects, and fully integrated microbial and mammalian facilities in Waltham, Massachusetts, and Vilnius, Lithuania.
KBI Biopharma Capacity Update October 2025: Large Molecule
Accelerate your biopharmaceutical program with a flexible, global manufacturing partner that minimizes risk, shortens timelines, and empowers seamless scaling from clinical to commercial production.
Boehringer Ingelheim Biopharmaceuticals GmbH Capacity Update October 2025: Large Molecule
This session provides a comprehensive overview of our biopharmaceutical contract manufacturing services for mammalian cell culture and microbial technologies.
Abzena Capacity Update October 2025: Large Molecule
Accelerate your therapeutic antibody and complex protein development with advanced mammalian cell line platforms that move from DNA to RCB in just 10 weeks.
Novartis Contract Manufacturing Capacity Update July 2025: Large Molecule Drug Substance
Review biologics CDMO solutions and capacity offered by Novartis Contract Manufacturing. We discuss our capabilities in mammalian cell culture manufacturing and microbial fermentation.
Providing Development And Supply Of Life-Changing Medicines
Review the strategic application of extensive expertise in microbial systems to meet the increasing demand for novel biologics. Cutting-edge capabilities ensure streamlined development and manufacturing processes.
Cytovance Biologics Capacity Update July 2025: Large Molecule Drug Substance
Thomas Kohl, Director of Business Development, shares the company’s microbial and mammalian capabilities and their available capacity. Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.
Aragen Capacity Update July 2025: Large Molecule Drug Substance
Aragen’s newly built cutting-edge biologics manufacturing facility launches with GMP capabilities from 50L to 2000L—scaling to 5000L soon—with a DP filling line and ADC conjugation suite set to redefine bioproduction in India.
Leveraging Advanced Tech, Proven Expertise From Cell Line Development And Beyond
Learn how our expertise and advanced capabilities provide customized analytical solutions that ensure quality, precision, and regulatory compliance for your biotherapeutics.
Cytovance Capacity Update July 2024: Large Molecule Development
Centrally located in the United States, with a decades-long history in biologics development and manufacturing, Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.
Agenda & Presenter Details
Visit our registration pages to see the current agenda and our list of presenting sponsors.
How can we help?
Are you a supplier looking to present at our next event?